InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,240.03
(
1.04%
)
US TECH 100
17,518.40
(
0.59%
)
Dow Jones
38,997.66
(
0.76%
)
Brent Oil
76.02
(
-1.48%
)
Bitcoin
56,271.36
(
4.22%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 95

Tuesday, 04/10/2018 7:02:01 PM

Tuesday, April 10, 2018 7:02:01 PM

Post# of 438
ATRS 9/29/18 is the PDUFA date for its subcutaneous testosterone treatment

Royalty revenues from AMAG's auto-injectable Makena should increase for mush of 2018.

Otrexup and their auto-injectable migraine treatment continue to grow

ANDAs for 3 TEVA-partnered generics have been submitted including an Epipen product that is a potential $500mn-plus opty.

In their latest reported Q, net loss fell to $3.7mn with cash equaling $31.6mn

* consider a run-up strategy after June earnings release.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up